Skip to main content

Table 5 IRs, IRRs, and 95 % confidence intervals of hepatic events without identified alternate etiology, follow-up through 15 days following treatment discontinuation, matched duloxetine and comparator cohorts, ORD, 01 August 2004 to 31 December 2010

From: Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database

Outcome

Cohort

Person-Years

No. Cases

IR

95 CI %

IRR

95 % CI

Hepatic-related death

Duloxetine

7633.5

0

0.0

(0.0, 0.4)

NA

NA

Venlafaxine

8838.7

0

0.0

(0.0, 0.3)

  

Duloxetine

10,411.9

0

0.0

(0.0, 0.3)

NA

NA

SSRI

9835.6

0

0.0

(0.0, 0.3)

  

Duloxetine

8116.7

0

0.0

(0.0, 0.4)

NA

NA

Untreated

5966.1

0

0.0

(0.0, 0.5)

  

Hepatic failure

Duloxetine

7631.7

0

0.0

(0.0, 0.4)

NA

NA

Venlafaxine

8836.6

0

0.0

(0.0, 0.3)

  

Duloxetine

10,410.6

0

0.0

(0.0, 0.3)

NA

NA

SSRI

9833.9

0

0.0

(0.0, 0.3)

  

Duloxetine

8116.2

0

0.0

(0.0, 0.4)

NA

NA

Untreated

5965.8

0

0.0

(0.0, 0.5)

  

Other clinically significant hepatic injurya

Duloxetine

7548.5

5

0.7

(0.2, 1.5)

undef.

(1.1, inf.)

Venlafaxine

8745.2

0

0.0

(0.0, 0.3)

  

Duloxetine

10,300.9

4

0.4

(0.1, 1.0)

undef.

(0.6, inf.)

SSRI

9753.2

0

0.0

(0.0, 0.3)

  

Duloxetine

8035.8

4

0.5

(0.1, 1.3)

1.0

(0.2, 6.7)

Untreated

5931.9

3

0.5

(0.1, 1.5)

  

Hepatic-related death and liver failure combined

Duloxetine

7631.7

0

0.0

(0.0, 0.4)

NA

NA

Venlafaxine

8836.6

0

0.0

(0.0, 0.3)

  

Duloxetine

10,410.6

0

0.0

(0.0, 0.3)

NA

NA

SSRI

9833.8

0

0.0

(0.0, 0.3)

  

Duloxetine

8116.2

0

0.0

(0.0,0.4)

NA

NA

Untreated

5965.6

0

0.0

(0.0, 0.5)

  

All clinically significant hepatic categories combined

Duloxetine

7548.5

5

0.7

(0.2, 1.5)

undef.

(1.1, inf.)

Venlafaxine

8745.2

0

0.0

(0.0, 0.3)

  

Duloxetine

10,300.9

4

0.4

(0.1, 1.0)

undef.

(0.6, inf.)

SSRI

9753.2

0

0.0

(0.0, 0.3)

  

Duloxetine

8035.8

4

0.5

(0.1, 1.3)

1.0

(0.2, 6.7)

Untreated

5931.9

3

0.5

(0.1, 1.5)

  

Non-serious hepatic enzyme elevation

Duloxetine

7548.5

1

0.1

(0.0, 0.7)

undef.

(0.0, inf.)

Venlafaxine

8745.2

0

0.0

(0.0,0.3)

  

Duloxetine

10,300.9

1

0.1

(0.0, 0.5)

0.5

(0.0, 9.1)

SSRI

9753.0

2

0.2

(0.0, 0.7)

  

Duloxetine

8035.8

1

0.1

(0.0, 0.7)

undef.

(0.0, inf.)

Untreated

5932.0

0

0.0

(0.0, 0.5)

  
  1. ORD Optum Research Database, IR incidence rate, representing number of events per 1000 person-years, CI confidence interval, IRR incidence rate ratio, NA not available, undef.undefined, inf. infinity
  2. aOne case of other clinically significant hepatic injury in the duloxetine cohort was initially confirmed by independent adjudicators as a confirmed case without alternate etiology. However, following a post hoc review by the adjudicators, this case was classified as a hepatic injury with alternate etiologies. Because we conducted this post hoc review outside of the protocol, the case remains in these data as a confirmed case without alternate etiology